Trevena Inc (EM) TRVN

Healthcare Biotechnology

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

EXPM:TRVN - Post by User

Trevena Inc (EM)

<< Previous

Bullboard Posts

Next >>

(13)
•••

Post by SandMan67on Aug 08, 2020 5:38am

396 Views

Post# 31382229

FDA site

On FDA site as well as 'popular news' sites. Trevena will do a press release Monday (hopefully before open) and the stock should respond for a nice gain. They will also publish qtrly earnings this week. I have a concern they will announce shares being issued to support this new business which could cause a slight dip later in the week but looks like a great long term hold (very good odds they are bought out by big pharma - Pfizer?).
https://www.fda.gov/news-events/press-announcements/fda-approves-new-opioid-intravenous-use-hospitals-other-controlled-clinical-settings

<< Previous

Bullboard Posts

Next >>

The USD 88 shock: Are UBS and Citigroup forcing the silver market to its knees, or are we witnessing the ultimate short squeeze? Opportunities at Silver North Resources